CYP2C19 progress curve analysis and mechanism-based inactivation by three methylenedioxyphenyl compounds

Drug Metabolism and Disposition

Volumn 39, Issue 12, 2011, Pages 2283-2289

  Salminen, Kaisa A ^a   Meyer, Achim ^b   Imming, Peter ^b   Raunio, Hannu ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BENZODIOXOLE DERIVATIVE; BULBOCAPNINE; CANADINE; CYTOCHROME P450 2C19; ISONIAZID; PROTOPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANYLCYPROMINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME KINETICS; IC 50; IN VITRO STUDY; PRIORITY JOURNAL;

APORPHINES; ARYL HYDROCARBON HYDROXYLASES; BENZOPHENANTHRIDINES; BERBERINE; BERBERINE ALKALOIDS; ENZYME INHIBITORS; HUMANS;

EID: 81855206601     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041319     Document Type: Article

References (39)

1. Abeles RH and Maycock AL (1976) Suicide enzyme inactivators. Acc Chem Res 9:313-319.
2. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, and Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293. (Pubitemid 36249683)
3. Casida JE (1970) Mixed-function oxidase involvement in the biochemistry of insecticide synergists. J Agric Food Chem 18:753-772.
4. Correia MA and Ortiz de Montellano PR (2005) Inhibition of cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano PR ed) pp 247-322, Kluwer Academic/Plenum Publishers, New York.
5. Donahue SR, Flockhart DA, Abernethy DR, and Ko JW (1997) Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 62:572-577. (Pubitemid 28214936)
6. Fontana E, Dansette PM, and Poli SM (2005) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413-454. (Pubitemid 41300789)
7. Franklin MR (1971) The enzymic formation of methylenedioxyphenyl derivative exhibiting an isocyanide-like spectrum with reduced cytochrome P-450 in hepatic microsomes. Xenobiotica 1:581-591.
8. Fukuto JM, Kumagai Y, and Cho AK (1991) Determination of the mechanism of demethylenation of (methylenedioxy)phenyl compounds by cytochrome P450 using deuterium isotope effects. J Med Chem 34:2871-2876.
9. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2006) A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7:315-334.
10. Gotti R (2011) Capillary electrophoresis of phytochemical substances in herbal drugs and medicinal plants. J Pharm Biomed Anal 55:775-801.
11. Grime KH, Bird J, Ferguson D, and Riley RJ (2009) Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36:175-191.
12. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metab Dispos 37:1355-1370.
13. Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70-83.
14. Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, and Mansuy D (2001) Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112-12122. (Pubitemid 32946552)
15. Hines RN and Prough RA (1980) The characterization of an inhibitory complex formed with cytochrome P-450 and a metabolite of 1,1-disubstituted hydrazines. J Pharmacol Exp Ther 214:80-86. (Pubitemid 10032386)
16. Jadhav VB, Nayak SK, Row TN, and Kulkarni MV (2010) Synthesis, structure and DNA cleavage studies of coumarin analogues of tetrahydroisoquinoline and protoberberine alkaloids. Eur J Med Chem 45:3575-3580.
17. Kalgutkar AS, Obach RS, and Maurer TS (2007) Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407-447. (Pubitemid 47603408)
18. Kent UM, Juschyshyn MI, and Hollenberg PF (2001) Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr Drug Metab 2:215-243. (Pubitemid 32782795)
19. Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, and Lu AY (2011) Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 36:1-16.
20. Muakkassah SF, Bidlack WR, and Yang WC (1981) Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism. Biochem Pharmacol 30:1651-1658. (Pubitemid 11072297)
21. Murray M (2000) Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab 1:67-84.
22. Nishimura Y, Kurata N, Iwase M, and Yasuhara H (2003) Mechanism-based inactivation of human CYP1A2 and CYP2C19 mediated metabolism by isoniazid. Drug Metab Rev 35:100.
23. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, and Raunio H (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667-715.
24. Polasek TM and Miners JO (2007) In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 3:321-329. (Pubitemid 47316027)
25. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
26. Riley RJ, Grime K, and Weaver R (2007) Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3:51-66. (Pubitemid 47315418)
27. Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, et al. (2005) Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin Pharmacol Ther 77:63-75.
28. Salminen KA, Leppänen J, Venäläinen JI, Pasanen M, Auriola S, Juvonen RO, and Raunio H (2011a) Simple, direct, and informative method for the assessment of CYP2C19 enzyme inactivation kinetics. Drug Metab Dispos 39:412-418.
29. Salminen KA, Meyer A, Jerabkova L, Korhonen LE, Rahnasto M, Juvonen RO, Imming P, and Raunio H (2011b) Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. Phytomedicine 18:533-538.
30. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283.
31. Taavitsainen P, Juvonen R, and Pelkonen O (2001) In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 29:217-222. (Pubitemid 32179519)
32. Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, and Kobayashi S (1999) Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol 47:454-457. (Pubitemid 29161281)
33. Vacek J, Walterova D, Vrublova E, and Simanek V (2010) The chemical and biological properties of protopine and allocryptopine. Heterocycles 81:1773-1789.
34. Venkatakrishnan K and Obach RS (2007) Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 8:449-462. (Pubitemid 47603409)
35. Vrba J, Vrublova E, Modriansky M, and Ulrichova J (2011) Protopine and allocryptopine increase mRNA levels of cytochromes P450 1A in human hepatocytes and HepG2 cells independently of AhR. Toxicol Lett 203:135-141.
36. Wada M, Yokoyama C, Hatae T, Shimonishi M, Nakamura M, Imai Y, Ullrich V, and Tanabe T (2004) Purification and characterization of recombinant human prostacyclin synthase. J Biochem 135:455-463. (Pubitemid 38660931)
37. Wang JF, Zhang CC, Chou KC, and Wei DQ (2009) Structure of cytochrome p450s and personalized drug. Curr Med Chem 16:232-244.
38. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833. (Pubitemid 41553963)
39. Zhang A, Zhang Y, Branfman AR, Baldessarini RJ, and Neumeyer JL (2007) Advances in development of dopaminergic aporphinoids. J Med Chem 50:171-181. (Pubitemid 46147697)